SEC filing · 8-K

Unicycive Therapeutics, Inc.: Executive or director change

Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate and appointed Meredith S. Manning to its board of directors.

Filed September 29, 2026

Positive for the company

What happened

Unicycive resubmitted its New Drug Application for oxylanthanum carbonate to treat hyperphosphatemia in chronic kidney disease patients on dialysis.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Unicycive Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.